GSK, the UK's second-biggest drugmaker, has unveiled a $2. 2bn (£1. 6bn) deal to acquire a Californian biotech company which is developing a drug to protect against severe food allergies, including allergies to nuts, milk and eggs.

(RTTNews) - GSK plc (GSK, GSK. L) announced that China's National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease or COPD characterised by raised blood eosinophils.